疏风解毒胶囊治疗急性病毒性上呼吸道感染对患者血清淀粉样蛋白A的影响

Effects of Shufengjiedu capsules on serum amyloid A in the treatment of patients with an acute viral upper respiratory tract infection

目的探讨疏风解毒胶囊治疗急性病毒性上呼吸道感染时对患者血清淀粉样蛋白A(SAA)的影响,并判断其疗效。方法急性病毒性上呼吸道感染患者220例,进行随机分组,其中110例为实验组(疏风解毒胶囊+常规治疗组),110例为对照组(常规对症治疗组),急诊就诊时和治疗72h及治疗1周检测血清淀粉样蛋白A(SAA)。结果实验组(疏风解毒胶囊组)治疗72h和1周血清SAA分别为(98.44±7.90)mg/L和(8.21±0.77)mg/L,对照组分别为(160.57±12.28)mg/L和(25.38±2.34)mg/L,差异有统计学意义(72h的F=2.42,P<0.05,1周的F=9.24,P<0.05)。愈显率实验组为68.00%,对照组为67.33%,差异无统计学意义(χ2=0.33,P>0.05)。疏风解毒胶囊的止咳作用优于常规对症治疗(χ2=13.71,P<0.05)。结论疏风解毒胶囊治疗急性病毒性上呼吸道感染具有降低患者血清淀粉样蛋白A(SAA)作用,且止咳作用显著。

Objectives To investigate the effects of Shufengjiedu capsules on serum amyloid A（SAA）and to determine their effectiveness in treating patients with an acute viral infection of the upper respiratory tract. Methods Two hundred and twenty patients with an acute viral upper respiratory tract infection were randomly divided into two groups,with110 patients in the experimental group（patients receiving Shufengjiedu capsules and routine treatment）and 110 patients in the control group（patients receiving routine treatment alone）.Body temperature was measured and the change in body temperature from when the patient was seen by the Emergency Department to 72 hafter treatment and 1week after treatment was determined.The patient’s cough score was assessed（guided by clinical research on traditional Chinese medicine）when the patient was seen by the Emergency Department,72 hafter treatment,and 1week after treatment.Similarly,SAA was measured when the patient was seen by the Emergency Department,72 hafter treatment,and 1week after treatment. Results The experimental group（the Shufengjiedu capsule group）had serum levels of SAA of 98.44±7.90mg/L 72 hafter treatment and 8.21±0.77mg/L 1week after treatment while the control group had serum levels of SAA of 160.57±12.28mg/L 72 hafter treatment and 25.38±2.34mg/L 1week after treatment.The difference in serum levels of SAA was statistically significant（72hafter treatment：F=2.42,P〈0.05,1week after treatment：F=9.24,P〈0.05）.The experimental group had a marked response rate of 68%（100patients）while the control group had a marked response rate of 67.33%（101patients）.The difference in the marked response rate was not significant（2=0.33,P〉0.05）.Cough symptoms disappeared 72 hafter treatment in 58%of the experimental group（100patients）and in40.59%of the control group（101patients）.Shufengjiedu capsules were better at alleviating a cough than conventional symptomatic treatment（χ2=13.71,P〈0.05）. Conclusion Shufengjiedu capsules decreased SAA in patients with an acute upper respiratory infection and markedly alleviated coughing.